Literature DB >> 10807775

beta2 microglobulin-deficient (B2m(null)) NOD/SCID mice are excellent recipients for studying human stem cell function.

O Kollet1, A Peled, T Byk, H Ben-Hur, D Greiner, L Shultz, T Lapidot.   

Abstract

Human SCID repopulating cells (SRC) are defined based on their functional ability to repopulate the bone marrow of NOD/SCID mice with both myeloid and lymphoid cell populations. The frequency of SRC in umbilical cord blood cells is 1 in 9.3 x 10(5) mononuclear cells. We report that as few as 8 x 10(4) human cord blood mononuclear cells transplanted into NOD/SCID/B2m(null )mice resulted in multilineage differentiation in the murine bone marrow, revealing a more than 11-fold higher SRC frequency than in NOD/SCID mice. Moreover, as few as 2 to 5 x 10(3) CD34(+) cells recovered from the bone marrow of primary transplanted NOD/SCID mice were sufficient for engrafting secondary NOD/SCID/B2m(null )mice with SRC, suggesting SRC self-renewal. Thus, by using NOD/SCID/B2m(null )mice as recipients, we established a functional assay for human stem cells capable of engrafting the bone marrow of primary and secondary transplanted immune-deficient mice with SRC, providing a model that better resembles autologous stem cell transplantation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10807775

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  39 in total

1.  Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function.

Authors:  T Ponomaryov; A Peled; I Petit; R S Taichman; L Habler; J Sandbank; F Arenzana-Seisdedos; A Magerus; A Caruz; N Fujii; A Nagler; M Lahav; M Szyper-Kravitz; D Zipori; T Lapidot
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

2.  Previously undetected human hematopoietic cell populations with short-term repopulating activity selectively engraft NOD/SCID-beta2 microglobulin-null mice.

Authors:  H Glimm; W Eisterer; K Lee; J Cashman; T L Holyoake; F Nicolini; L D Shultz; C von Kalle; C J Eaves
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

Review 3.  Hematopoietic stem cells.

Authors:  Robert G Hawley; Ali Ramezani; Teresa S Hawley
Journal:  Methods Enzymol       Date:  2006       Impact factor: 1.600

4.  Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment.

Authors:  Yoshitaka Iso; Jeffrey L Spees; Claudia Serrano; Benjamin Bakondi; Radhika Pochampally; Yao-Hua Song; Burton E Sobel; Patrick Delafontaine; Darwin J Prockop
Journal:  Biochem Biophys Res Commun       Date:  2007-01-17       Impact factor: 3.575

5.  Fluorophore-conjugated iron oxide nanoparticle labeling and analysis of engrafting human hematopoietic stem cells.

Authors:  Dustin J Maxwell; Jesper Bonde; David A Hess; Sarah A Hohm; Ryan Lahey; Ping Zhou; Michael H Creer; David Piwnica-Worms; Jan A Nolta
Journal:  Stem Cells       Date:  2007-11-29       Impact factor: 6.277

6.  Isolation and therapeutic potential of human haemopoietic stem cells.

Authors:  Andrew D Clark; Heather G Jørgensen; Joanne Mountford; Tessa L Holyoake
Journal:  Cytotechnology       Date:  2003-03       Impact factor: 2.058

Review 7.  Concise review: ex vivo expansion of cord blood-derived hematopoietic stem and progenitor cells: basic principles, experimental approaches, and impact in regenerative medicine.

Authors:  Patricia Flores-Guzmán; Verónica Fernández-Sánchez; Hector Mayani
Journal:  Stem Cells Transl Med       Date:  2013-10-07       Impact factor: 6.940

8.  Factors affecting human T cell engraftment, trafficking, and associated xenogeneic graft-vs-host disease in NOD/SCID beta2mnull mice.

Authors:  Bruno Nervi; Michael P Rettig; Julie K Ritchey; Hanlin L Wang; Gerhard Bauer; Jon Walker; Mark L Bonyhadi; Ronald J Berenson; Julie L Prior; David Piwnica-Worms; Jan A Nolta; John F DiPersio
Journal:  Exp Hematol       Date:  2007-08-30       Impact factor: 3.084

9.  A xenograft model of macrophage activation syndrome amenable to anti-CD33 and anti-IL-6R treatment.

Authors:  Mark Wunderlich; Courtney Stockman; Mahima Devarajan; Navin Ravishankar; Christina Sexton; Ashish R Kumar; Benjamin Mizukawa; James C Mulloy
Journal:  JCI Insight       Date:  2016-09-22

10.  Immunodeficient mouse strains display marked variability in growth of human melanoma lung metastases.

Authors:  Beatriz M Carreno; Joel R Garbow; Grant R Kolar; Erin N Jackson; John A Engelbach; Michelle Becker-Hapak; Leonidas N Carayannopoulos; David Piwnica-Worms; Gerald P Linette
Journal:  Clin Cancer Res       Date:  2009-05-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.